<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708861</url>
  </required_header>
  <id_info>
    <org_study_id>MARAT</org_study_id>
    <secondary_id>2014-004692-22</secondary_id>
    <nct_id>NCT03708861</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients</brief_title>
  <official_title>Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe pharmacokinetics of maraviroc (MVC) 300 mg and
      atazanavir/ritonavir (ATV/r) 200/100 mg QD in HIV-infected stable patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rational of this study is to save therapeutic options, toxicity and costs. The available
      literature shows that antiretroviral regimens that do not include a nucleoside backbone of
      tenofovir resulted in less bone and kidney toxicity. Atazanavir dosing 200/100 mg qd
      represents a simplification strategy correlated with virologic efficacy and a reduction of
      parameters toxicity associated. Maraviroc is suggested as a possible drug associated to PI/r
      in dual therapies. Even in this case, the available evidence supports the choice of the
      dosage of 300 mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maraviroc (300 mg, QD) + atazanavir/ritonavir (200/100 mg, QD) pharmacokinetic evaluation</measure>
    <time_frame>within the first 16 weeks after switch</time_frame>
    <description>percentage of patients with maraviroc Ctrough&gt;50ng/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>viral suppression evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>percentage of patients with HIV-RNA&lt;20 cp/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>modification in CD4 count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone density evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>modification in bone mineral density (DEXA femur and spine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone metabolism markers evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>modification in bone metabolism markers (bALP and vitamin D, PTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glomerular and tubular renal function evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>modification of proteinuria, glycosuria, phosphaturia and GFR;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid metabolism markers evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>modification in total, HDL, LDL cholesterol and triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bilirubin evaluation</measure>
    <time_frame>week 60</time_frame>
    <description>changes in total bilirubin levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>MVC + ATV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)</intervention_name>
    <description>Phase 1: switch from tenofovir disoproxil fumarato/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).
Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)</description>
    <arm_group_label>MVC + ATV/r</arm_group_label>
    <other_name>CELSENTRI</other_name>
    <other_name>REYATAZ</other_name>
    <other_name>NORVIR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years; confirmed HIV-antibodies positivity; signed informed consent; HIV-RNA
             &lt;20 cp/ml for last 24 months, at least; no virological failures to PI regimens; no
             major PI resistance associated mutations;genotypic tropism for CCR5 co-receptor.

        Exclusion Criteria:

          -  active opportunistic infections or neoplasms; need for drugs with known drug-drug
             interactions with included drugs; liver cirrhosis; any evidence of tropism for CXCR4
             or dual infection; pregnancy; self-reported adherence&lt;90%; HBsAg positivity;
             detectable HCV RNA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 14, 2018</last_update_submitted>
  <last_update_submitted_qc>October 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Giovanni Di Perri</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>maraviroc, atazanavir/ritonavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

